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Summary: The timing of antiretroviral therapy (ART) initiation for HIV and tuberculosis (TB) co-infected patients
needs to be considered carefully. CD4 cell count can be used to guide decision making about when to initiate ART.
Evidence from recent randomized trials and observational studies generally supports early initiation but does not
provide information about effects of initiation time on a continuous scale. In this paper, we develop and apply a
highly flexible structural proportional hazards model for characterizing the effect of treatment initiation time on a
survival distribution. The model can be fitted using a weighted partial likelihood score function. Construction of both
the score function and the weights must accommodate censoring of the treatment initiation time, the outcome, or
both. The methods are applied to data on 4903 individuals with HIV/TB co-infection, derived from electronic health
records in a large HIV care program in Kenya. We use a model formulation that flexibly captures the joint effects
of ART initiation time and ART duration using natural cubic splines. The model is used to generate survival curves
corresponding to specific treatment initiation times; and to identify optimal times for ART initiation for subgroups
defined by CD4 count at time of TB diagnosis. Our findings potentially provide ‘higher resolution’ information about
the relationship between ART timing and mortality, and about the differential effect of ART timing within CD4
subgroups.
Key words: Antiretroviral therapy (ART); Electronic health records; Informative censoring; Inverse weighting;
Marginal structural model; Time-varying confounders.
This paper has been submitted for consideration for publication in Biometrics
ar
X
iv
:1
90
4.
01
93
2v
1 
 [s
tat
.A
P]
  2
 A
pr
 20
19
11. Introduction
1.1 Overview and Objectives
Co-infection with HIV and tuberculosis (TB) is a significant public health issue in the
developing world. Investigation of the most effective strategies for integration of antiretroviral
therapy (ART) for HIV with standard treatment for tuberculosis (TB) has been a topic of
intensive research, including at least three major randomized controlled trials (RCT) (Havlir
et al., 2011; Abdool Karim et al., 2011; Blanc et al., 2011). Current World Health Organi-
zation (WHO) guidelines recommend immediate initiation of TB therapy, with concomitant
or closely sequenced ART for HIV, depending on presentation at diagnosis (WHO, 2013).
Initiating ART too early increases the potential for drug toxicity and the risk of TB-
associated immune reconstitution inflammatory syndrome (IRIS), a potentially fatal con-
dition (Havlir et al., 2011). On the other hand, late initiation of ART increases risk for
morbidity and mortality associated with AIDS (Abdool Karim et al., 2010). Although
optimal timing of ART initiation during the TB treatment period is difficult to determine
(Abdool Karim et al., 2011), evidence from randomized trials strongly supports earlier
initiation for those who have advanced HIV disease at the time of TB diagnosis, with more
equivocal conclusions for those at less advanced stages (Havlir et al., 2011; Abdool Karim
et al., 2011; Blanc et al., 2011).
Although randomized trials form a strong evidence base, limitations remain. First, the
randomized trials compare protocols defined in terms of time intervals for ART initiation,
rather than actual timing. Second, the sample sizes are relatively small, with participants
distributed over multiple sites, in some cases in different countries within the same trial.
Third, randomized trials are by necessity conducted under tightly controlled conditions,
and may not fully reflect the experience of patients in routine care settings. Data derived
from electronic health records (EHR) provide an opportunity to augment the evidence base
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using larger-scale data collected in a representative care setting. In particular, EHR enables
investigation of the effect of ART timing at higher resolution because actual initiation times
are available and subgroups of interest have larger sample sizes. However, any analysis of EHR
and other types of observational data must address issues related to nonrandom treatment
allocation, irregular sampling, and complex missing data patterns.
In this paper we develop a modeling framework for drawing causal inferences about the
timing of treatment initiation when the outcome is an event time; in this case, time to death.
We apply the model to data drawn from the medical records of individuals enrolled in the
Academic Model Providing Access to Healthcare (AMPATH), a large-scale HIV care program
in western Kenya (Einterz et al., 2007). The data have rich information, but the observational
nature of the data poses several complications for our analysis. First, treatment initiation
time is not randomly allocated. Second, many individuals have incomplete information on
exposure, outcome, or both. For example, some patients died before initiating ART, which
censors ART initiation time; for others, incomplete follow up leads to censoring of death
time, ART initiation time, or both. Figure 1 shows the four observed-data patterns of ART
initiation and mortality following initiation of TB treatment. Third, the functional form of
the causal effect of initiation time on mortality rate is not known.
[Figure 1 about here.]
To address these issues, we formulate a structural causal hazard model that captures the
effects of both timing and duration of ART on hazard of mortality using unspecified smooth
functions, and we derive methods for generating consistent estimates of model parameters
under nonrandom treatment allocation and complex censoring patterns. Using output from
the fitted model, we generate estimates of the functional causal relationship between ART
timing and mortality. Our method can be used to estimate the survival distribution — and
therefore any functional of the survival distribution — associated with any specific ART
initiation time. Our analyses of the AMPATH data uses one-year survival as the primary
3endpoint because it is consistent with one of the major randomized trials (Havlir et al.,
2011), but any functional of the survival distribution could be used.
This paper is organized as follows: the remainder of Section 1 provides additional back-
ground on issues related to HIV/TB co-infection and reviews statistical approaches related
to estimating causal effect of treatment timing. Section 2 describes notation, defines optimal
initiation time, and provides detailed specification of our marginal structural proportional
hazards model. Section 3 develops the methods for fitting the model to observational data
where both treatment timing and death time are subject to censoring. Section 4 presents
results from applying our analysis of AMPATH data, with emphasis on new insights that
can be gained, relative to findings from randomized trials. Section 5 summarizes a simulation
study that examines properties of model-based inferences. In Section 6 we put the results in
context by comparing them with RCT findings and current treatment guidelines, and outline
directions for further research.
1.2 Treatment of Individuals Co-infected with HIV and Tuberculosis
Generally, treatment of TB itself is a 6-month regimen. The World Health Organization
(WHO) recommends that TB treatment should be initiated first, with ART initiated within
the first 8 weeks for all patients and within the first 2 weeks for those with CD4 less than 50.
However, complications associated with early initiation of ART may discourage treatment
adherence and cause adverse effects resulting from drug interactions and IRIS (WHO, 2013).
Recent RCTs provide an evidence base for these recommendations. For brevity, ART
initiation time is hereafter defined relative to the start of TB treatment, and measured in
weeks. The AACTG study A5221 found reduced 48-week mortality in the CD4<50 subgroup,
comparing the early (0−2) to the late (8−12) initiation arm (Havlir et al., 2011). The SAPIT
trial recorded significantly higher mortality rate for the initiating interval 24− 28 compared
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to 0− 4 or 8− 12 (Abdool Karim et al., 2011). In the CAMELIA trial, significantly reduced
hazard of death was found in the early initiation arm (2 versus 8) (Blanc et al., 2011).
The question of ART timing has also been examined in at least three observational studies.
An analysis of 322 co-infected patients from Spain showed longer survival for those starting
ART in the first 2 months of TB treatment, compared to 3 months (Velasco et al., 2009).
A prospective cohort study of 667 individuals in Thailand demonstrated an increased risk
of death with longer delays in ART initiation (Varma et al., 2009). An analysis of 308 co-
infected adults in Rwanda concluded that early ART initiation reduced mortality in persons
with CD4 count below 100 (Franke et al., 2011).
1.3 Data Source: AMPATH Medical Record System (AMRS)
AMPATH provides care to over 160,000 HIV-positive individuals at 143 sites in western
Kenya. The AMPATH Medical Record System (AMRS), one of the largest of its kind in
sub-Saharan Africa, contains more than 100 million clinical observations from over 300,000
enrolled patients (Rachlis et al., 2015). Our analysis makes use of clinical encounter data
from 4903 adults with HIV/TB co-infection drawn from the AMRS between March 1, 2004
and April 18, 2008. The dataset contains individual-level information at baseline on the
following variables: age, gender, WHO stage (a 4-level ordinal diagnostic indicator of HIV
severity), weight, CD4 count, clinic visit (urban versus rural), marital status and post-
primary education. The dataset includes also longitudinal information on ART initiation
status, death, and CD4 count. Among all patients presenting with HIV/TB co-infection,
26% have incomplete information on ART initiation time (case III and IV in Figure 1).
These data were generated before the findings from the studies referenced above were
released; this, combined with the exercise of clinical judgment in making treatment decisions,
yields significant variation in ART initiation time, even among those whose clinical profiles
are similar in terms of recorded information.
51.4 Statistical Methods for Treatment Duration and Timing
Our methods address inference about causal effect of treatment initiation time on a survival
distribution. The related problem of causal effect of treatment duration (assuming initiation
time is the same for everyone) has been investigated in two papers by Johnson and Tsiatis
(2004, 2005); the first considers the case where duration is discrete and the second extends
to the more complex case of continuous time. In both cases, duration time is subject to
censoring that may be related to measured covariates, and inverse probability weighting
is used to address nonrandom treatment allocation. Both papers restrict attention to the
mean or regression function related to a single endpoint; in our setting, we use survival time
as the endpoint, which introduces the need to deal with censoring of both the exposure
and the endpoint. Our approach to inference builds on Johnson and Tsiatis (2004, 2005),
particularly as it relates to the use of a Radon-Nikodym derivative for deriving appropriate
weight functions (see also Murphy et al., 2001). Work by Xiao et al. (2014) uses regression
splines to model the weighted sum of treatment duration and estimate the effect of cumulative
exposure to ART. Our model includes a term for treatment duration as a function of time,
separately captures effect of timing, and allows the effect of duration to depend on timing
(provided sufficient data are available).
The analysis by Franke et al. (2011), referenced above, uses a model that has a similar
formulation to ours. They use pooled logistic regression with inverse probability weights to
fit a marginal structural model to a sample from 308 individuals. Our paper formalizes that
approach for continuous-time settings and considerably relaxes distributional assumptions
about the underlying potential outcomes distributions.
The fitted model can be used to estimate the entire distribution of potential outcomes
corresponding to a given initiation time. The estimated causal relationships are highly data-
driven in the sense that key parts of the structural model are left unspecified, including the
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baseline hazard function, the instantaneous effect of treatment as a function of initiation
time, and the effect of treatment duration once initiated. The added versatility of our model
is motivated by the desire to take full advantage of the information available in our much
larger cohort (which, to our knowledge, is larger than any cohort associated with a published
analysis on HIV/TB co-infection).
2. Formulation of Potential Outcomes Model
2.1 Notation for Potential Outcomes and Observed Data
Let t denote time elapsed from the initiation of TB therapy, and let tmax denote maximum
follow-up time. Let Ta > 0 denote the potential outcome corresponding to time of death
under the scenario that ART is initiated at time a, where a > 0 is continuous. We use T∞
to denote death time corresponding to any a > tmax.
Information on potential outcomes is observed according to the cases depicted in Figure 1.
Let A be the random variable representing ART initiation time and let T = TA denote
the survival time corresponding to initiating ART at A. Let C denote a censoring time. As
shown in Figure 1, either or both of A and TA may be right censored, for example due to
loss to follow up. The observed data available for drawing inference about the distribution
of potential outcomes are as follows: the observed follow up time for the mortality outcome
is T ∗ = min(T,C), with event indicator ∆T = I(T < C). Similarly, the observed follow
up time for ART initiation time is A∗ = min(A, T ∗) = min(A, T, C), with event indicator
∆A = I(A < T ∗). Notice that A can be right censored by T , as shown in Case II of Figure 1.
Because large ART initiation times are infrequently observed in our data, we administratively
censor A and T ∗ at tmax for cases where A > tmax and T ∗ > tmax, respectively.
Each individual has p covariates, some of which may be time varying. We use L(t), t > 0 to
denote the p×1 vector containing the most recently observed value of each covariate at time
7t, with L(t) = {L(s) : 0 6 s < t} representing the observed covariate history up to but not
including t. For each individual, therefore, we observe a copy of
{
L(A∗), T ∗,∆T , A∗,∆A
}
.
The letter A was originally used for AZT (zidovudine) and L for lymphocyte cell count in
earlier causal inference literature (Miguel Hernan, personal communication).
2.2 Marginal Structural Model for Mortality
We assume Ta follows a marginal structural proportional hazards model of the form
λa(t) = λ∞(t) r(t, a), (1)
where λa(t) is the hazard function for Ta, λ∞(t) is the reference hazard for T∞, and r(t, a) > 0
is the (time-dependent) hazard ratio function. We parameterize r(t, a) in terms of three
functions, g1(a), g2(t− a) and g3(a(t− a)), respectively denoting effects of timing, duration,
and timing-duration interaction. Specifically, we assume
r(t, a) = exp [I(a < t) {g1(a) + g2(t− a) + g3(a(t− a))}] , (2)
where g1(·), g2(·) and g3(·) are unspecified smooth functions that are twice continuously
differentiable, with the second derivative set to zero at the interval boundaries for a, t − a
and a(t−a). The hazard function λa(t) can depend on baseline covariates L(0) by elaborating
model (2) or by using a stratified version of λ∞(t), as demonstrated in Section 4.
The model can be understood by considering some simple cases. Figure 2 illustrates three
simplified versions of the hazard model and the corresponding survival models. For clarity,
models in Figure 2 assume λ∞(t) is constant (our model allows it to remain unspecified)
and assumes g3(a(t − a)) = 0 (no interaction between a and t − a). In Figure 2(a), we set
g1(a) = β1 and g2(t−a) = 0, which implies the log hazard of mortality is log{λ∞(t)} prior to
treatment initiation (t < a) and β1+log{λ∞(t)} thereafter (t > a). This version assumes the
instantaneous effect of initiating ART on hazard of mortality is not a function of initiation
timing. In Figure 2(b), we allow g1(a) to vary with a, so that the effect of ART initiation
8 Biometrics, 000 0000
does depend on its timing. In Figure 2(c), we additionally set g2(t−a) = (t−a)β2, where β2
is a scalar, which implies that the instantaneous effect of initiating ART is g1(a), and that
the effect of being on ART at any given time t depends on duration.
[Figure 2 about here.]
Turning to the more general formulation, we parameterize g1(·), g2(·) and g3(·) using
natural cubic splines constructed from piecewise third-order polynomials that pass through
a set of control points, or knots. A natural cubic spline has continuous first and second
derivatives at the knots, and is linear beyond the boundary knots. Basis functions generated
under these constraints are called B-spline functions (Hastie et al., 2009). Parameterizing (2)
in terms of B-splines yields
λa(t) = λ∞(t) exp
[
I(a < t)
{
b>1 (a)β1 + b
>
2 (t− a)β2 + b>3 (a(t− a))β3
}]
, (3)
where b1(·) = (b11(·), . . . , b1K1 (·))> is a K1 × 1 vector representing a B-spline basis function
of degree K1 in a, and b2(·) = (b21(·), . . . , b2K2 (·))> and b3(·) = (b31(·), . . . , b3K3 (·))>, having
dimension K2 × 1 and K3 × 1, respectively, are defined similarly as functions of t − a and
a(t− a). The parameters β1, β2 and β3 are, respectively, K1 × 1, K2 × 1 and K3 × 1 vectors
of coefficients for the basis functions b1(·), b2(·) and b3(·). The model for the risk function
can be written in compact form as r(t, a) = exp{X>(a, t)β}, where
X(a, t) (K1+K2+K3)×1 = I(a < t)[b
>
1 (a), b
>
2 (t− a), b>3 (a(t− a))]> (4)
and β (K1+K2+K3)×1 = (β
>
1 , β
>
2 , β
>
3 )
>. The causal effect of ART initiation time on the survival
distribution is therefore encoded in β, and the formulation in terms of B-spline basis functions
allows the use of weighted proportional hazards regression methods to obtain consistent
estimates of β.
93. Estimation of Structural Model and Optimal Initiation Time
3.1 Overview
In our data, the decision to initiate ART depends on information available to the physi-
cian, and is therefore not randomly allocated. Moreover, A will be right censored when an
individual dies or leaves the study before treatment initiation. We propose to estimate β
by maximizing an inverse-probability-weighted partial likelihood score function. We show
how to construct and estimate weights that lead to consistent estimates of β under specific
assumptions about treatment allocation and censoring, and in Web Appendix Section 1, we
provide a heuristic justification based on the use of Radon-Nikodym derivatives (Murphy
et al., 2001).
In deriving the weighted estimating equations for β, we first consider the hypothetical case
where A is not randomized and where T is always observed. Next, we move to the case where
A may be censored by T (i.e., where death occurs prior to treatment initiation), but there
is no censoring by C. We then describe the case where A is not randomized, and possibly
censored by T . Finally, we generalize our approach to allow for censoring by C. We then
show how to construct causal contrasts between different treatment initiation times using
output from the fitted model.
3.2 Randomized Treatment Assignment
If treatment is randomly allocated according to a known probability density fA(·), we can
use the standard partial likelihood score equations to derive consistent estimators of β. For
this simple case we assume A is observed for everyone and there is no censoring by C. For
t > 0, let NT (t) = I
{
T 6 t,∆T = 1
}
denote the zero-one counting process associated with
T . Let Y (t) = 1 if an individual is still at risk for death and under observation at t, and
Y (t) = 0 otherwise. The partial likelihood score equations can be written
∑n
i=1Di(β) = 0,
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where
Di(β) = D(Ai, Ti; β)
=
∫ ∞
0
{
X(Ai, t)−X(t, β)
}
dNTi (t), (5)
where X(Ai, t) is the design matrix based on (4) and
X(t, β) =
∑
kX(Ak, t)Yk(t)r(Ak, t; β)∑
k Yk(t)r(Ak, t; β)
.
Let ER(·) denote expectation under randomized treatment assignment. Under randomization
of A, n−1
∑
iD(Ai, Ti; β) is an unbiased estimator of ER {D(A, T ; β)}. The estimating func-
tion
∑
iDi(β) is a stochastic integral of a predictable process with respect to a martingale,
and as such ER {D(A, T ; β0)} = 0 at the true value β0 of β; hence, the root β̂ of the estimating
equation
∑n
i=1Di(β) = 0 is a consistent estimator of β (Fleming and Harrington, 2005, pp.
297-298).
Now consider the case where A is still randomly allocated, but death may occur before
initiation of treatment, so that A∗ = min(A, T ) and ∆A = I(A < T ). We continue to assume
no censoring by C. Following Johnson and Tsiatis (2005), the mean of an individual score
contribution can be represented as the sum of contributions from those with observed and
censored values of A; i.e., ER {D(Ai, Ti; β)} = ER
{
∆Ai D(Ai, Ti; β) + (1−∆Ai )D(Ai, Ti; β)
}
.
Contributions corresponding to censored values of A have expectation
ER
{
(1−∆Ai )D(Ai, Ti; β)
}
= ER
[
ER
{
(1−∆Ai )D(Ai, Ti; β)
∣∣∆Ai , A∗i }]
= ER
[
(1−∆Ai )ER
{
D(Ai, Ti; β)
∣∣∆Ai , A∗i }]
= ER
{
(1−∆Ai )
∫ ∞
A∗i
D(a, Ti, β)dF
A |A>A∗i (a)
}
= ER
{
(1−∆Ai )
1− FA(A∗i )
∫ ∞
A∗i
D(a, Ti, β)dF
A(a)
}
. (6)
To evaluate (6), note that D(a, Ti; β) =
∫∞
0
{X(a, t) − X(t, β)}dNTi (t), and recall that
X(a, t) = I(a < t)[b>1 (a), b
>
2 (t − a), b>3 (a(t − a))]>, so that X(a, t) = 0 for a > t. This
11
implies D(a, Ti, β) is a constant function of a, with D(a, Ti, β) = −X(Ti, β) for a > A∗i
and 0 otherwise. The integral in (6) therefore reduces to −X(Ti, β){1 − FA(A∗)}, and the
expectation itself reduces to ER
{−(1−∆Ai )X(Ti, β)}.
Pulling this all together, we see that when death may occur before treatment initiation,
and when there is no censoring by C, n−1
∑
iDi(β) is an unbiased estimator of
ER
{
∆AD(A, T ; β)− (1−∆A)X(T, β)}, which implies that the solution β̂ to the modified
estimating equations
n∑
i=1
{
∆Ai D(Ai, Ti; β)− (1−∆Ai )X(Ti, β)
}
= 0 (7)
will yield a consistent estimator of β.
3.3 Non-random Allocation of Treatment
Suppose now that A is not randomly allocated, but that treatment allocation can be con-
sidered ignorable in the sense that
λA(t |L(t),T{a>t}) = λA(t |L(t)), (8)
where T{a>t} = {Ta : a > t} is the set of potential failure times associated with initiation
times beyond t. This assumption states that initiation of treatment at time t is sequentially
randomized in the sense that it is independent of future potential outcomes, conditionally
on observed covariate history L(t) (Robins, 1999).
Let PR(·) denote the data distribution under randomized treatment, and let PO(·) denote
the same under non-random allocation of treatment. Recall that the observable data for
each individual, under either randomized or non-randomized allocation of treatment, is
{A∗,∆A, T ∗,∆T}. Following Murphy et al. (2001) and Johnson and Tsiatis (2005), under
the sequential randomization assumption in (8) and some regularity conditions, includ-
ing the positivity assumption referenced in Web Appendix Section 1, the distribution of
{A∗,∆A, T ∗,∆T} under PR(·) is absolutely continuous with respect to the distribution of
12 Biometrics, 000 0000
{A∗,∆A, T ∗,∆T} under PO(·), and a version of the Radon-Nikodym (R-N) derivative is
EO
{
∆A fA(A∗)
fA(A∗ |L(A∗)) +
(1−∆A)(1− FA(A∗))
1− FA(A∗ |L(A∗))
∣∣∣∣ A∗ = a,∆A = δA, T ∗ = t,∆T = δT} . (9)
An estimating equation that is a function of observed data and is unbiased under the dis-
tribution of PR(·) can be re-weighted by the R-N derivative to obtain an unbiased estimating
equation using the same observed data, but now under the distribution PO(·) (Murphy et al.,
2001). Define weights WA1i and W
A
2i as
WA1i(t) =
fA(t)
fA(t |Li(t))
, WA2i(t) =
1− FA(t)
1− FA(t |Li(t))
.
The R-N derivative in (9) suggests using the weighted estimating equation
n∑
i=1
∆Ti
{
∆Ai D
∗(Ai, Ti; β)WA1i(Ai)− (1−∆Ai )X∗(Ti; β)WA2i(Ti)
}
= 0, (10)
where D∗ and X
∗
are evaluated using weighted risk set indicators
Y ∗i (t) = Yi(t)
{
I(Ai < t)W
A
1i(Ai) + I(Ai > t)WA2i(t)
}
.
Up to now we have assumed no censoring by C. Let NA(t) = I{A 6 t,∆A = 1}, for
t > 0, denote the zero-one counting process for treatment initiation, with N
A
(t) representing
treatment history information up to time t. Similarly, define NC(t) = I(C 6 t,∆T = 0). We
assume that censoring at t can depend on covariate and treatment history, but conditionally
on these is independent of future potential outcomes. This assumption can be expressed
formally in terms of the hazard function associated with NC(t),
λC(t |NA(t), L(t), T{a>t}) = λC(t |NA(t), L(t)). (11)
As with the treatment initiation process, we can define a weight function associated with
censoring,
WCi (t) =
1− FC(t)
1− FC(t |NA(t), Li(t))
.
This leads to a final modification of the estimating equations for β to accommodate covariate-
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and treatment-dependent censoring,
Un(β) =
n∑
i=1
∆Ti W
C
i (Ti)
{
∆Ai D
∗∗(Ai, Ti; β)WA1i(Ai)− (1−∆Ai )X∗∗(Ti; β)WA2i(Ti)
}
, (12)
where D∗∗ and X
∗∗
are evaluated using weighted risk set indicators
Y ∗∗i (t) = Yi(t)W
C
i (t)
{
I(Ai < t)W
A
1i(Ai) + I(Ai > t)WA2i(t)
}
.
Writing (12) in terms of counting process notation used in (5) makes the distinct contribu-
tions of the four observation patterns in Figure 1 more transparent,
Un(β) =
n∑
i=1
∫ ∞
0
WCi (t)
[
∆Ai W
A
1i(Ai)
{
X(Ai, t)−X∗∗(t; β)
}
− (1−∆Ai )WA2i(t)X∗∗(t; β)
]
dNTi (t).
In particular all individuals censored by C, either before or after initiating treatment (cases
II and IV in Figure 1), contribute information about β via contributions to the risk set up
to the observed censoring time C.
3.4 Estimation of the Weights
The weights in (12) depend on the marginal and conditional density functions of A and C,
which can be estimated from fitted models of the marginal and conditional intensity processes
associated with NA(t) and NC(t). To estimate fA(t |L(t)), we assume λA(t |L(t)) follows a
proportional hazards regression parameterized using a finite-dimensional parameter αA,
λA(t |L(t)) = λA0 (t) rA(L(t); αA), (13)
where r is a user-specified regression function. (We use a proportional hazards formulation
for convenience, but any regression formulation can be used here). The conditional density
function fA(t |L(t)) can be estimated using the empirical cumulative hazard,
ΛA(t |L(t), α̂A) =
∫ t
0
rA(L(s); α̂A)dN(s)∑
j Yj(s)r
A(L(s); α̂A)
1− FA(t |L(t), α̂A) = exp{−ΛA(t |L(t), α̂A)} ,
f̂A(t |L(t)) = λA(t |L(t), α̂A){1− FA(t |L(t), α̂A)} ,
where α̂A is the maximum partial likelihood estimator for model (13).
14 Biometrics, 000 0000
To estimate the unknown marginal probability density fA(t), we use the Nelson-Aalen
estimator Λ̂A(t) =
∑
i
∫ t
0
dNAi (s)/Yi(s) for the cumulative hazard function and λ̂
A(t) =
dΛ̂A(t) for the hazard function. The estimated CDF and density functions are obtained
using F̂A(t) = 1 − exp{−Λ̂A(t)} and f̂A(t) = λ̂A(t){1 − F̂A(t)}, respectively. The weight
estimators are therefore a function of F̂A, f̂A, and α̂A,
ŴA1i(t) =
f̂A(t)
f̂A(t |Li(t))
, ŴA2i(t) =
1− F̂A(t)
1− FA(t |Li(t), α̂A)
.
The weights WCi (t) can be estimated in a similar fashion by specifying and fitting a regression
model of the form λC(t |NA(t), L(t)) = λC0 (t) rC(NA(t), L(t), αC) to obtain estimates of
fC(t |NA(t), L(t)) and FC(t |NA(t), L(t)), and using the Nelson-Aalen estimator
Λ̂C(t) =
∑
i
∫ t
0
dNCi (s)/Yi(s) to obtain estimates of f
C(t) and FC(t).
3.5 Optimal Initiation Time
Referring back to our structural hazard model (2), the survival function for the potential
outcome Ta corresponding to initiation time a is Sa(t) = exp{−Λa(t)}, where
Λa(t) = I(t < a)Λ∞(t)
+ I(t > a)
[
Λ∞(a) +
∫ t
a
exp{g1(a) + g2(u− a) + g3(a(u− a))}dΛ∞(u)
]
. (14)
The g functions are estimated using weighted partial likelihood score as described above, and
the baseline cumulative hazard Λ∞(t) is estimated using the (weighted) Breslow estimator
that arises from the fitting process. The survivor function Sa(t) can therefore be estimated for
any combination of a and t, enabling estimation of specific causal contrasts such as mortality
ratios Sa(t)/Sa′(t) for a 6= a′.
With sufficient amounts of data, we also can use model output to infer optimal timing for
treatment initiation. An optimal initiation time is defined as the value of a that maximizes an
objective function written in terms of a functional of the distribution of potential outcomes.
Specifically, let Fa(t) = P (Ta 6 t) denote the CDF associated with Ta, and let θa = θ(Fa)
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denote a scalar functional of Fa (e.g., the mean
∫
t dFa(t) or median F
−1
a (
1
2
)). For a given
functional θa, the optimal initiation time is aopt = arg maxa θa.
In our application we use one-year survival θa = 1 − Fa(t0), with t0 set to 52 weeks, as
the primary endpoint. Our estimates of aopt were somewhat unstable because the one-year
mortality curve as a function of initiation time appears to be monotone increasing from
zero (i.e., nonconvex). Alternatively, we compare mortality rates for contextually motivated
initiation time intervals (trials referenced in Section 1) to draw inferences about optimal
timing. We elaborate in Section 4.
4. Application to AMPATH data
Our analysis dataset contains 4903 HIV/TB co-infected patients who had TB therapy
initiated and had a CD4 count below 350 at the start of TB therapy. Under guidelines
in place at the time, these patients were eligible for ART initiation. Baseline (t = 0) is
defined as the time of TB treatment initiation. The total number of deaths is 541. To avoid
influence of sparsely distributed large values of ART initiation times, we administratively
censor the data at 1.5 years (tmax). Of the 3302 patients in case II and 1060 patients in case
IV of Figure 1, 1335 and 38 were administratively censored at tmax, respectively.
At the time when these data were collected, baseline CD4 was a key marker used to decide
ART initiation time. To be consistent with AMPATH guidelines, we divide baseline CD4
count into groups defined by the intervals [0, 50], (50, 200], (200, 350]. Median weeks to ART
initiation is 4 for CD4 6 50, 8 for CD4 ∈ (50, 200] and 12 for CD4 ∈ (200, 350].
Baseline covariates and time-varying CD4 count (1.9 CD4 measures per year per person)
were used to fit the hazard models λA(t |L(t)) and λC(t |NA(t), L(t)) leading to treatment
and censoring weights. Each model included the main effect of each covariate; higher-order
polynomial terms for continuous variables were tested and found not to add information.
Estimated model coefficients are summarized in Web Table 2. Bootstrap re-sampling with
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1000 replicates is used to estimate standard errors of the estimated mean one-year survival;
censoring and ART initiation time models are re-fit within each bootstrap sample.
All calculations are carried out in R. The hazard models for ART initiation time and
censoring time are fitted using R function coxph. The structural model given by (3) is
fitted using weighted partial likelihood, also using coxph (Therneau, 2015), with spline basis
functions for g1(a), g2(t − a) and g3(a(t − a)) generated using the R function ns. We place
knots at the 25th, 50th and 75th percentile of the uncensored values of A∗ for g1(·); T ∗−A∗
for g2(·); and A∗(T ∗ − A∗) for g3(·).
In Web Appendix Section 3, we describe steps of fitting the structural model (3), show
plots of each estimated g function, and summarize key findings from the plots. Plots of g
functions for the CD650 subgroup appear in Figure 3.
[Figure 3 about here.]
The plot of ĝ1(a) in the first panel of Figure 3 shows that the instantaneous effect of ART
initiation is U-shaped, with maximum benefit (lowest mortality hazard) just after 10 weeks,
and lower effectiveness with longer delays. In the second panel, ĝ2(t−a) depicts the effect of
treatment duration, and generally indicates that longer duration times are associated with
lower mortality hazard. The increasing trend in the interaction term ĝ3(a(t − a)) suggests
that delayed ART initiation reduces the effect of duration on treatment. The quadratic trend
in ĝ1(a) supports the notion that immediate treatment initiation carries some risk of elevated
mortality that is possibly balanced out by the benefit of remaining on treatment longer. The
net causal effect is summarized in plots comparing one-year mortality rate between regimes
a and a′, where a = 0 and a′ > 0 (Figure 5, described below).
Figure 4 shows estimated mortality curves, derived using (14), for selected ART initiation
times a ∈ {0, 8, 24,∞} and stratified by baseline CD4 subgroup. Differences between these
curves are causal contrasts. For each distinct value of a, mortality rate is clearly highest for
those with baseline CD4 ∈ [0, 50]. Looking within CD4 strata, comparing curves for a = 0
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and a = 8 to those with a > 8 suggests a benefit of early initiation for all groups, with
greatest benefit for those in the lowest CD4 stratum. Figure 5 shows one-year mortality
and the causal treatment effect Ŝa(52) − Ŝ0(52) as a function of treatment initiation time,
stratified by baseline CD4 subgroup. The effect of early initiation is most pronounced for
CD4 6 50. The results suggest immediate initiation for CD46 200. Diagnostic plots suggest
the model fits the data well (Web Figure 4).
[Figure 4 about here.]
[Figure 5 about here.]
Finally, we can emulate comparisons between regimens reported in the randomized trials
cited earlier. We can mimic random allocation of treatment initiation time to specific intervals
by assuming a distribution for A that is independent of outcomes and covariates, and
compare interval-specific mortality rates to draw inferences about treatment timing. In our
data example, we assume A follows a uniform distribution, and calculate one-year survival
probability associated with initiating in a given interval [t1, t2) via
∫
a∈[t1,t2){1−F̂a(t0)}dFU(a),
where FU(·) is the CDF of the uniform distribution on [0, tmax]. To illustrate, following the
SAPIT trial, we compare one-year mortality for initiating intervals [0, 4] and [8, 12] weeks.
For those with CD4 6 50 (n = 1540), our model estimated the mean mortality rate to be
.16 (.14, .19) for [0, 4] and .20 (.17, .24) for [8, 12], with a p-value of .02 for the difference
between the means, as compared to .10 and .20 respectively for the two regimens from the
trial (n = 72), with a p-value of .17 for the incidence-rate ratio.
Our results suggest ART should be initiated within 8 weeks of the initiation of TB therapy
for AMPATH patients with CD4 counts lower than 200. There is a marked increase in
expected one-year mortality when ART is initiated after 8 weeks (see Figure 5). For patients
with CD4 ∈ (200, 350], while early initiation still results in lowest one-year mortality, there
is not strong statistical evidence to support the conclusion that a specific ART initiation
time (or time interval) will lead to reduced one-year mortality. Our results are consistent
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with AMPATH guidelines (Web Table 3) in treating HIV/TB co-infected patients, and are
consistent with general findings of randomized controlled trials.
5. Simulation
We conducted a simulation to study properties of our weighted estimator when the model
is correctly specified and to evaluate sensitivity of the weighted estimator to violations of
the no unmeasured confounding assumption. We simulate data from a simplified version of
our structural model (1). We examine bias, variability and confidence interval coverage rates
related to estimates of one-year mortality for different choices of a under three scenarios: 1)
under random allocation of treatment; 2) with measured confounding and 3) in the presence
of unmeasured confounding. The simulation results show near-zero bias and nominal coverage
probability for Scenario 1. In the presence of measured confounding (Senario 2), the weighted
estimator eliminates nearly all the bias and coverage probabilities are close to nominal levels
as compared to the unweighted estimator. Unmeasured confounding (Scenario 3) produces
bias in proportion to the degree of confounding. We provide details about the data generation
algorithm, the parameter values and results in Web Appendix Section 2.
6. Summary and Discussion
Timing of ART initiation is important in HIV/TB co-infection. Determining the optimal
ART initiation time is difficult because of the need to achieve balance between the risk
for mortality and potential adverse events associated with early antiviral therapy initiation.
Three randomized controlled trials (AACTG, SAPIT, and CAMELIA) support earlier initi-
ation of ART for those with very low CD4 count, but initiation times are quantified on an
interval scale. Our data, derived from electronic health records, allow higher-resolution in-
ference for initiation time on a continuous scale, are sampled from a well-defined population,
and reflect outcomes from actual clinical practice.
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Our results are largely consistent with the findings of the clinical trials, and provide
important reinforcement and elaboration of those findings. Our model provides estimates
of mortality for any potential initiation time ranging from 0 to 40 weeks, and moreover it
captures the separate effects of ART initiation and ART duration. This latter feature enables
examination of the potential trade-offs associated with early initiation, illustrated in Figure 3.
In addition to reinforcing the findings from recent trials, inference about grouped-interval-
based optimal initiation times for ART are consistent with current AMPATH guidelines.
Our model assumes that both treatment initiation and censoring are independent of
potential mortality outcomes, conditionally on baseline and time-dependent covariates. Given
that treatment decisions are based on clinical indicators that we included in our weight
model, the treatment ignorability assumption has substantive justification. It is possible
that censoring could be associated with higher death rate. In the future, we will develop
formal representations of potential selection biases, and use those as a basis for examining
sensitivity to violations of assumptions about ignorable treatment assignment and censoring.
Our model, though flexible, can be extended in several directions. First, an important
structural assumption is that the effects of initiation, duration and their interaction are
additive on the log hazard scale; this requirement could be relaxed by introducing a multi-
dimensional spline function. Fitting this sort of model would likely require a larger dataset.
Second, our model considers regimens that are static in the sense that they are dependent on
a baseline covariate (here, CD4 count). A potential topic of further research is comparison of
dynamic treatment regimes, which are defined in terms of an individual’s evolving history;
e.g., ‘initiate ART when CD4 first drops below x’ (Robins et al., 2008). Although we consid-
ered this approach, in AMPATH — as in most resource-constrained HIV care environments
— data needed for these comparisons are limited because CD4 and other HIV disease markers
are measured infrequently (typically every six months, but sometimes less often).
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Finally, focused clinical questions that have generated considerable data from both ran-
domized trials and observational studies are potentially fertile ground for development of new
methods that combine, synthesize or compare available evidence. This activity has particular
importance in the field of HIV, where large observational databases are forming the basis for
important and far-reaching policy related to treatment and policy interventions (Gu¨nthard
et al., 2016).
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Figure 1. Patterns of observed information on ART initiation time A and death time T .
Either or both may be right censored prior to one year at time C.
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(a) g1(a1) = g1(a2) = −.5; g2(a) = 0
(b) g1(a1) = −1.5; g1(a2) = −.5; g2(a) = 0
(c) g1(a1) = −1.5; g1(a2) = −.5; g2(a) = −.5(t− a)
Figure 2. Simple examples of the hazard models and corresponding survival models; Two
initialization times are compared: a1 = .5; a2 = 2.
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Figure 3. Fitted curves g1(a), g2(t−a) and g3(a(t−a)), for baseline CD4650. See model (2).
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Figure 4. Estimated mortality functions 1− Ŝa(t) corresponding to ART initiation times
a ∈ {0, 8, 24, ∞}.
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Figure 5. Top panel: causal effect of ART initiation: one-year mortality as a function of
ART initiation time. Bottom panel: difference in one-year mortality between initiating ART
at time a and concomitant initiation with TB treatment. Stratified by baseline CD4 count.
